Meeting
2018 ASCO Annual Meeting
EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.
Authors
Hope S. Rugo
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Hope S. Rugo , Johannes Ettl , Natasha E. Woodward , Sara A. Hurvitz , Anthony Goncalves , Kyung-Hun Lee , Louis Fehrenbacher , Rinat Yerushalmi , Lida A. Mina , Miguel Martin , Henri Hubert Roche , Young-Hyuck Im , Denka Markova , Iulia Cristina Tudor , Wolfgang Eiermann , Joanne Lorraine Blum , Alison L. Hannah , Jennifer Keating Litton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT01945775
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1069)
DOI
10.1200/JCO.2018.36.15_suppl.1069
Abstract #
1069
Poster Bd #
150
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).
First Author: Jennifer Keating Litton
Poster
2019 ASCO Annual Meeting
Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.
First Author: Johannes Ettl
Poster
2023 ASCO Annual Meeting
Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC).
First Author: David Graham